439 related articles for article (PubMed ID: 4136226)
1. Abnormalities of chemotactic lymphokine synthesis and mononuclear leukocyte chemotaxis in Wiskott-Aldrich syndrome.
Altman LC; Snyderman R; Blaese RM
J Clin Invest; 1974 Aug; 54(2):486-93. PubMed ID: 4136226
[TBL] [Abstract][Full Text] [Related]
2. Phagocyte function and immunological findings in a Wiskott-Aldrich syndrome long-term survivor.
Capsoni F; Acerbi L; Bonora G; Perletti L; Ongari AM; Vanoli M; Zanussi C
J Clin Lab Immunol; 1986 Feb; 19(2):91-7. PubMed ID: 3754288
[TBL] [Abstract][Full Text] [Related]
3. A diagnostic assay for the Wiskott-Aldrich syndrome and its variant forms.
Siminovitch KA; Greer WL; Novogrodsky A; Axelsson B; Somani AK; Peacocke M
J Investig Med; 1995 Apr; 43(2):159-69. PubMed ID: 7735919
[TBL] [Abstract][Full Text] [Related]
4. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages.
Postlethwaite AE; Kang AH
J Immunol; 1979 Aug; 123(2):561-7. PubMed ID: 458146
[TBL] [Abstract][Full Text] [Related]
5. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism.
Blaese RM; Strober W; Levy AL; Waldmann TA
J Clin Invest; 1971 Nov; 50(11):2331-8. PubMed ID: 5096517
[TBL] [Abstract][Full Text] [Related]
6. Disorders of regulatory T cell function in patients with the Wiskott-Aldrich syndrome.
Zabay JM; Fontán G; Campos A; García-Rodriguez MC; Pascual-Salcedo D; Bootello A; de la Concha EG
Clin Exp Immunol; 1984 Apr; 56(1):23-8. PubMed ID: 6609033
[TBL] [Abstract][Full Text] [Related]
7. Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome.
Oppenheim JJ; Blaese RM; Waldmann TA
J Immunol; 1970 Apr; 104(4):835-44. PubMed ID: 4986478
[No Abstract] [Full Text] [Related]
8. Monocyte chemotactic responsiveness triggered by Lymphocyte-Derived Chemotactic Factor in aged donors. Definitive report.
Antonaci S; Jirillo E; Serlenga E; Bonomo L
Lymphokine Res; 1985; 4(4):359-65. PubMed ID: 3876494
[TBL] [Abstract][Full Text] [Related]
9. The Wiskott-Aldrich syndrome. Results of transfer factor therapy.
Spitler LE; Levin AS; Stites DP; Fudenberg HH; Pirofsky B; August CS; Stiehm ER; Hitzig WH; Gatti RA
J Clin Invest; 1972 Dec; 51(12):3216-24. PubMed ID: 4640955
[TBL] [Abstract][Full Text] [Related]
10. Phytohaemagglutinin-induced cytotoxic effector lymphocyte function in patients with the Wiskott-Aldrich syndrome (WAS).
Sherwood G; Blaese RM
Clin Exp Immunol; 1973 Apr; 13(4):515-20. PubMed ID: 4736825
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficiency in the Wiskott-Aldrich syndrome.
Blaese RM; Strober W; Waldmann TA
Birth Defects Orig Artic Ser; 1975; 11(1):250-4. PubMed ID: 238675
[TBL] [Abstract][Full Text] [Related]
12. Studies of the expression of the Wiskott-Aldrich syndrome protein.
Stewart DM; Treiber-Held S; Kurman CC; Facchetti F; Notarangelo LD; Nelson DL
J Clin Invest; 1996 Jun; 97(11):2627-34. PubMed ID: 8647957
[TBL] [Abstract][Full Text] [Related]
13. Characterization of guinea pig lymphocyte-derived chemotactic factor for fibroblasts.
Postlethwaite AE; Kang AH
J Immunol; 1980 Mar; 124(3):1462-6. PubMed ID: 7358987
[TBL] [Abstract][Full Text] [Related]
14. Abnormal immune responses in the ocular presentation of Wiskott-Aldrich syndrome.
Guss RB; McCulley JP
Ann Ophthalmol; 1982 Nov; 14(11):1058-60. PubMed ID: 7181336
[TBL] [Abstract][Full Text] [Related]
15. Contributions of Wiskott-Aldrich syndrome family cytoskeletal regulatory adapters to immune regulation.
Zhang J; Dong B; Siminovitch KA
Immunol Rev; 2009 Nov; 232(1):175-94. PubMed ID: 19909364
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.
Vilmer E; Lenoir GM; Virelizier JL; Griscelli C
Clin Exp Immunol; 1984 Feb; 55(2):249-56. PubMed ID: 6321070
[TBL] [Abstract][Full Text] [Related]
17. Effect of transfer factor on lymphocyte function in anergic patients.
Kirkpatrick CH; Rich RR; Smith TK
J Clin Invest; 1972 Nov; 51(11):2948-58. PubMed ID: 5080419
[TBL] [Abstract][Full Text] [Related]
18. The in vitro response of peripheral blood lymphocytes from patients with Wiskott-Aldrich syndrome.
Marinkovich VA
Clin Allergy; 1972 Mar; 2(1):69-78. PubMed ID: 4275189
[No Abstract] [Full Text] [Related]
19. [Wiskott-Aldrich syndrome].
Erttmann R; Thöne I; Landbeck G
Monatsschr Kinderheilkd; 1983 Aug; 131(8):524-7. PubMed ID: 6605477
[TBL] [Abstract][Full Text] [Related]
20. Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory responses to therapy with transfer factor.
Levin AS; Spitler LE; Stites DP; Fudenberg HH
Proc Natl Acad Sci U S A; 1970 Oct; 67(2):821-8. PubMed ID: 5289024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
